Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 28: | Line 28: | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Marginal zone lymphoma medications]] | [[Category:Marginal zone lymphoma medications]] | ||
| + | [[Category:Mast cell diseases]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
Revision as of 02:28, 28 October 2014
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
Also known as
2-chlorodeoxyadenosine, 2-CdA, Litak, Movectro
References
Categories:
- Drug index
- Antimetabolites
- Purine analogues
- Chemotherapy
- Irritant chemotherapy
- Nucleic acid analogs
- Acute myeloid leukemia medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Hairy cell leukemia medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mast cell diseases
- Waldenström macroglobulinemia medications